RudaCure Inc., a venture company specializing in the development of treatments for sensory disorders, announced on the 30th that its self-developed dry eye disease treatment candidate substance RCI001 has been recognized for its commercialization potential and has been selected for the Ministry of Trade, Industry and Energy's 'R&D Rediscovery Project,' the Ministry of SMEs and Startups' '2020 BIG3 Sector SME Innovation Growth Support Project,' and Incheon Technopark's 'Startup Park Project,' thereby laying the foundation for clinical trials.
https://www.donga.com/news/It/article/all/20200729/102213491/2